Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
Open Access
- 24 September 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 114 (13), 2721-2729
- https://doi.org/10.1182/blood-2009-02-205500
Abstract
Here we describe the generation of an antibody–drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker. By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti–CD79b-vcMMAE could be widely used in these malignancies. By using NHL cell lines to simulate a patient population we discovered that a minimal cell-surface expression level of CD79b was required for in vitro activity. Within the subpopulation of cell lines above this minimal threshold, we found that sensitivity to free MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activity; however, the expression level of BCL-XL was correlated with reduced sensitivity to anti–CD79b-vcMMAE. This observation was supported by in vivo data showing that a Bcl-2 family inhibitor, ABT-263, strikingly enhanced the activity of anti–CD79b-vcMMAE. Furthermore, anti–CD79b-vcMMAE was significantly more effective than a standard-of-care regimen, R-CHOP (ie, rituximab with a single intravenous injection of 30 mg/kg cyclophosphamide, 2.475 mg/kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 days), in 3 xenograft models of NHL. Together, these data suggest that anti–CD79b-vcMMAE could be broadly efficacious for the treatment of NHL.Keywords
This publication has 24 references indexed in Scilit:
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphomaJournal of Clinical Oncology, 2008
- Antibody-Drug Conjugates for Cancer TherapyThe Cancer Journal, 2008
- Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphomaBlood, 2007
- Safety of rituximab maintenance therapy in follicular lymphomasLeukemia Research, 2006
- A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow CytometryImmunological Investigations, 2006
- Arming antibodies for cancer therapyCurrent Opinion in Pharmacology, 2005
- Non-Hodgkin lymphoma: an updateThe Lancet Oncology, 2004
- Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disordersAmerican Journal of Hematology, 2000
- Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complexMolecular Immunology, 1994